Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) hit a new 52-week low during trading on Tuesday . The company traded as low as $78.81 and last traded at $80.00, with a volume of 5769 shares traded. The stock had previously closed at $79.82.

A number of equities analysts have commented on BMRN shares. Cantor Fitzgerald set a $135.00 target price on shares of Zimmer Biomet and gave the stock a “buy” rating in a research note on Friday, April 26th. Raymond James restated a “hold” rating on shares of Snc-Lavalin Group in a research note on Tuesday, April 9th. BidaskClub downgraded shares of Zai Lab from a “strong-buy” rating to a “buy” rating in a research note on Friday. Wedbush upgraded shares of NINTENDO LTD/ADR from a “neutral” rating to an “outperform” rating in a research note on Wednesday, July 10th. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Sunday, June 2nd. Two analysts have rated the stock with a sell rating, four have issued a hold rating and thirteen have given a buy rating to the stock. BioMarin Pharmaceutical has an average rating of “Buy” and an average price target of $115.54.

The company has a quick ratio of 2.76, a current ratio of 3.83 and a debt-to-equity ratio of 0.28. The firm’s 50 day moving average is $83.04. The firm has a market cap of $14.21 billion, a PE ratio of -245.09 and a beta of 1.36.

In related news, Director V Bryan Lawlis sold 3,750 shares of the stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $81.08, for a total transaction of $304,050.00. Following the completion of the sale, the director now owns 27,340 shares of the company’s stock, valued at $2,216,727.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jean Jacques Bienaime sold 10,000 shares of the stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $82.52, for a total transaction of $825,200.00. Following the sale, the chief executive officer now directly owns 336,520 shares of the company’s stock, valued at approximately $27,769,630.40. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 17,750 shares of company stock worth $1,457,890. Insiders own 1.97% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. Jennison Associates LLC lifted its position in BioMarin Pharmaceutical by 7.0% during the first quarter. Jennison Associates LLC now owns 12,412,593 shares of the biotechnology company’s stock valued at $1,102,611,000 after acquiring an additional 812,133 shares during the last quarter. Geode Capital Management LLC lifted its position in BioMarin Pharmaceutical by 6.0% during the fourth quarter. Geode Capital Management LLC now owns 1,643,507 shares of the biotechnology company’s stock valued at $139,844,000 after acquiring an additional 92,519 shares during the last quarter. Pictet Asset Management Ltd. lifted its position in BioMarin Pharmaceutical by 4.6% during the first quarter. Pictet Asset Management Ltd. now owns 1,362,755 shares of the biotechnology company’s stock valued at $121,054,000 after acquiring an additional 59,728 shares during the last quarter. First Trust Advisors LP lifted its position in BioMarin Pharmaceutical by 16.0% during the first quarter. First Trust Advisors LP now owns 1,261,908 shares of the biotechnology company’s stock valued at $112,095,000 after acquiring an additional 174,499 shares during the last quarter. Finally, Northern Trust Corp raised its holdings in shares of BioMarin Pharmaceutical by 1.7% in the first quarter. Northern Trust Corp now owns 1,202,314 shares of the biotechnology company’s stock worth $106,801,000 after buying an additional 20,108 shares during the last quarter. 98.51% of the stock is owned by institutional investors.

About BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Further Reading: Inflation

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.